Ki8751

Ki8751

CAT N°: 18004
Price:

From 91.00 77.35

Vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR and FLK1) is a receptor tyrosine kinase that regulates angiogenesis, vascular development, and embryonic hematopoiesis in response to VEGF isoforms A, C, and D. Ki8751 is a potent, orally available inhibitor of the kinase activity of VEGFR2 (IC50 = 0.9 nM).{31021} It less potently inhibits c-Kit, PDGRF?, and FGFR2 (IC50s = 40-170 nM) and has no significant effect against several other receptor tyrosine kinases. Ki8751 suppresses the growth of VEGF-stimulated human umbilical vein endothelial cells at nanomolar concentrations.{31021} It shows significant anti-tumor activity against assorted human tumor xenografts in nude mice.{31021} Ki8751 also induces cellular senescence in colorectal cancer cells.{31020}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-(2,4-difluorophenyl)-N’-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]-urea
  • Correlated keywords
    • vascular endothelial growth factor VEGFR-2 KDR Flk-1 VEGFR2 FLK1 Ki 8751 HUVEC
  • Product Overview:
    Vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR and FLK1) is a receptor tyrosine kinase that regulates angiogenesis, vascular development, and embryonic hematopoiesis in response to VEGF isoforms A, C, and D. Ki8751 is a potent, orally available inhibitor of the kinase activity of VEGFR2 (IC50 = 0.9 nM).{31021} It less potently inhibits c-Kit, PDGRF?, and FGFR2 (IC50s = 40-170 nM) and has no significant effect against several other receptor tyrosine kinases. Ki8751 suppresses the growth of VEGF-stimulated human umbilical vein endothelial cells at nanomolar concentrations.{31021} It shows significant anti-tumor activity against assorted human tumor xenografts in nude mice.{31021} Ki8751 also induces cellular senescence in colorectal cancer cells.{31020}

We also advise you